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Theiler's murine encephalomyelitis virus
Inﬁltrates
Microglia
AdenosineInﬂammation in the central nervous system (CNS) is a complex process that involves a multitude of mole-
cules and effectors, and it requires the transmigration of blood leukocytes across the blood–brain barrier
(BBB) and the activation of resident immune cells. Cannabidiol (CBD), a non-psychotropic cannabinoid
constituent of Cannabis sativa, has potent anti-inﬂammatory and immunosuppressive properties. Yet, how
this compound modiﬁes the deleterious effects of inﬂammation in TMEV-induced demyelinating disease
(TMEV-IDD) remains unknown. Using this viral model of multiple sclerosis (MS), we demonstrate that CBD de-
creases the transmigration of blood leukocytes by downregulating the expression of vascular cell adhesion
molecule-1 (VCAM-1), chemokines (CCL2 and CCL5) and the proinﬂammatory cytokine IL-1β, as well as by
attenuating the activation of microglia. Moreover, CBD administration at the time of viral infection exerts
long-lasting effects, ameliorating motor deﬁcits in the chronic phase of the disease in conjunction with reduced
microglial activation and pro-inﬂammatory cytokine production. Adenosine A2A receptors participate in some of
the anti-inﬂammatory effects of CBD, as the A2A antagonist ZM241385 partially blocks the protective effects of
CBD in the initial stages of inﬂammation. Together, our ﬁndings highlight the anti-inﬂammatory effects of CBD
in this viral model of MS and demonstrate the signiﬁcant therapeutic potential of this compound for the treat-
ment of pathologies with an inﬂammatory component.
© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license. Introduction
MS is a chronic, inﬂammatory demyelinating disease of the CNS
that is characterized pathologically by the presence of focal areas of
inﬂammatory-mediated demyelination in the white matter of the
brain and spinal cord (Trapp and Nave, 2008). The etiology of MS re-
mains unknown, although several factors including genetic predispo-
sition, viral infection and autoimmunity are thought to be involved.
In the early stages of the disease, there is a recruitment of activated
immune cells that promotes the adhesion and transmigration ofidiol; CCL2, chemokine ligand
ptor 2; CNS, central nervous
elitis; MS, multiple sclerosis;
ncephalomyelitis virus-induced
al and Systems Neurobiology,
. Dr. Arce 37, 28002, Madrid,
irect.com).
nc.Open access under CC BY-NC-ND lileukocytes across the BBB (Archelos et al., 1999; Lee and Benveniste,
1999; Ransohoff, 1999). These events depend on a variety of interactions,
including an initial transient contact between circulating leukocytes
and the vascular endothelium, mediated by adhesion molecules, and
the binding of leukocytes to chemotactic chemokines present on the
endothelial surface. This latter event promotes the expression of
integrins on the leukocyte surface and ultimately, it leads to diapedesis
and leukocyte entry into the CNS (Engelhardt, 2008). It is widely recog-
nized that enhanced leukocyte trafﬁcking to the CNS is a key feature
of MS (Lassmann, 2008). Therapies have been designed to target CNS
inﬂammation, such as natalizumab (Tysabri®), a humanized antibody
to very late antigen-4 (VLA-4: Krumbholz et al., 2012) that is essen-
tial for the homing of immune cells to the brain and other organs.
Indeed, natalizumab is currently prescribed for the treatment of re-
lapsing remitting MS (Steinman, 2012). Similarly, cannabis-based
medicines containing tetrahydrocannabinol (THC) and CBD have
also been approved for the treatment of pain and spasticity in MS
(e.g., Sativex®). The promising therapeutic potential of cannabinoids
(reviewed by Pertwee, 2012) is limited due to the central CB1
receptor-mediated psychotropic effects. CBD is themajor Cannabis de-
rived non-CB1/CB2 ligand that is devoid of psychotropic effects and
even, inhibits many central effects of THC (Zuardi, 2008). Evidence
shows that CBD acts as an immunomodulator (Mechoulam et al.,
2007) and exhibits a wide range of anti-inﬂammatory propertiescense. 
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pathways in microglial cells (Kozela et al., 2010). CBD has been shown
to induce apoptosis of microglial cells through lipid raft involvement
(Wu et al., 2012). Moreover, CBD ameliorates experimental auto-
immune encephalomyelitis (EAE) symptomatology by diminishing
inﬂammation, microglial activity and leukocyte inﬁltrates in the spi-
nal cord (Kozela et al., 2011).
CBD has a broad spectrum of pharmacological actions (Izzo et al.,
2009) including the inhibition of an equilibrative nucleoside transporter
which in turn led to the increase of extracellular adenosine (Carrier et al.,
2006). In acute injury models CBD diminishes inﬂammation through
adenosine A2 receptors (Ribeiro et al., 2012). Neuroprotective effects
of CBD in hypoxic–ischemic brain damage also involve adenosine A2 re-
ceptors (Castillo et al., 2010).
We previously reported that enhanced endocannabinoid tone and
treatment with synthetic cannabinoid agonists improve motor be-
havior in TMEV-IDD mice, reducing inﬁltration into the spinal cord
(Arevalo-Martin et al., 2003; Correa et al., 2005; Docagne et al., 2007;
Ortega-Gutierrez et al., 2005). However, the effects of CBD in the induc-
tion phase of TMEV-IDD have not been previously described. In the
present study, we investigated the effects of CBD in the initial stages
of the inﬂammatory response in the TMEV-IDD experimental model of
MS, and the impact of this treatment on the symptomatology and the
neuroinﬂammation that characterizes the chronic phase of the disease.
Finally, we investigated the contribution of adenosine A2A receptors to
these effects of CBD.
Materials and methods
Animals and Theiler's virus infection
TMEV-IDD-susceptible female SJL/J mice from our in-house colony
(Cajal Institute, Madrid) were maintained on a 12 h light/dark cycle
with ad libitum access to food and water. Four-week-old mice were
inoculated intracerebrally in the right hemisphere with 2 × 106 plaque
forming units (PFU) of the Daniels (DA) strain of TMEV in 30 μl of
Dulbecco's Modiﬁed Eagle's Medium (DMEM) supplemented with
10% fetal calf serum (FCS), as described previously (Lledo et al., 1999),
or with 30 μl of DMEM + 10% FCS in the case of sham (non-infected)
operatedmice. Animals were handled in accordance with the European
Union animal care guidelines (2010/63/EU).
In vivo CBD and ZM241385 treatments
ShamorTMEV-IDDmicewere administeredwithCBD(5 mg/kg, kindly
provided by Dr. Mechoulam from the University of Jerusalem, Israel) intra-
peritoneally (i.p.) or the vehicle alone, once daily from days 1 to 7
post-infection (p.i.) for the analysis at induction and from days 1 to 10 p.i.
to analyze the long-term effects. The duration of the treatmentwas chosen
based on previous studies using the TMEV-IDD model (Docagne et al.,
2007;Mestre et al., 2005; Ortega-Gutierrez et al., 2005). To identify the im-
plication of A2A receptors in the effects of CBD, the ZM241385 antagonist
(5 mg/kg) was injected to control (sham), TMEV and CBD treated animals
30 min before treatment with the cannabinoid, according to the work of
Ribeiro et al. (2012). Animals for the analysis at induction were sacriﬁced
with an overdose of anesthetic (pentobarbital) 8 days p.i., while those
treated for 10 days were maintained in the animal facility for 80 days p.i.,
when signs of disease were evident in the TMEV-infected mice. At this
point, the motor activity was evaluated and the animals were sacriﬁced
and processed for tissue collection.
Behavioral analysis: spontaneous motor activity
Locomotor activity was evaluated in mice using an activity cage
(Activity Monitor System, Omnitech Electronics Inc., Columbus, OH,
USA) coupled to a Digiscan Analyser. The number of times that theanimals broke the horizontal or vertical sensor beams was measured
in two 5-min sessions.
Tissue processing
Micewere anesthetized with pentobarbital (50 mg/kg body weight,
i.p.) and perfused with saline. The animals' brain and spinal cord were
ﬁxed overnight in 4% paraformaldehyde prepared in 0.1 M phosphate
buffer (PB) and cryoprotected in sucrose solution in 0.1 M PB (15%
followed by a 30%). Coronal cryostat sections (30 μm thick) were then
processed for immunohistochemistry.
Immunohistochemistry
Free-ﬂoating brain or spinal cord sections were washed three
times for 10 minwith 0.1 MPB and blocked for 1 h at room temperature
in blocking buffer (0.1% Triton X-100 and 5% normal goat serum: Vector
Laboratories, Burlingame, CA, USA) after inhibiting the endogenous per-
oxidase. The sections were then incubated overnight at 4 °C in blocking
buffer containing the antibodies against VCAM-1 (1:1000; DSHB, USA)
or Iba-1 (1:1000; Wako, Osaka, Japan). The following day, the sections
were rinsed three times for 10 min with PB + 0.1% Triton X-100 and
they were then incubated for 1 h with a biotinylated (Vector Laborato-
ries, CA, USA) or Alexa Fluor-conjugated (Molecular Probes Inc, Eugene,
OR, USA) goat anti-rabbit antibody. For immunoﬂuorescence, the sec-
tions were then rinsed three times for 10 min with PB and mounted.
For immunostaining with DAB, the sections were incubated for 1 h
with a biotin-peroxidase complex (Vector Laboratories, CA, USA) and
ﬁnally with the chromogen 3,3′ diaminobenzidine tetrahydrochloride
(DAB: Sigma-Aldrich, St. Louis, MO, USA). After staining, the sections
were dehydrated, cleared with xylene and coverslipped. In all cases, the
speciﬁcity of staining was conﬁrmed by omitting the primary antibody.
Microscopy and image analysis
Images were acquired for immunoﬂuorescence on a Leica TCS SP5
confocal microscope and for immunohistochemistry with a Zeiss
Axiocam high resolution digital color camera. Individual images of
4–5 sections were acquired from at least 6 animals per group. The im-
munostaining quantiﬁcation was performed using ImageJ software
(designed by National Institutes of Health) as detailed as follows:
ﬁrst, we deﬁned the regions of interest (white matter in cervical spi-
nal cord, whole area in cerebral cortex) with the freehand tool; sec-
ond, we split the channels of the selected area, obtaining one image
per channel; third, we established a constant threshold of intensity
in sham animals to apply it to all the experimental groups; and four,
we measured the staining intensity of all images within the experi-
ments. The data are presented as the percentage of the total area that
was stained with respect to sham animals.
Inﬂammatory inﬁltrate analysis
Slices were stained with hematoxylin and eosin (H&E) and the
inﬂammatory inﬁltrate was evaluated by scoring the amount of inﬁl-
trates on a scale of 0–4 in speciﬁc brain areas (cortex and striatum)
and in blood vessels. A score of 0 reﬂects the absence of inﬁltrates, 4
reﬂects the highest amount of inﬁltrates, while all the intermediate
scores (1, 2 and 3) deﬁne the increasing density of inﬁltrates in the
brain tissue. Representative images showing scale inﬁltrates 1–4 are
presented in the Supplementary data.
Endothelial cell culture and stimulation with TMEV virus
Murine brain endothelial cells (b.end5)with brain endothelium-like
properties were obtained from the European Collection of Cell Cultures
(UK). The cells were plated in 12-well plates at a density of 105 cells/ml
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fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml strepto-
mycin, and in a humidiﬁed atmosphere of 5% CO2. The cells were
maintained in these conditions for 1 day and they were then switched
to restricted growth conditions (1% FBS) 1 h before the experiments.
CBD (Tocris, Bristol, UK) was added 1 h prior to infection of the cells
with the DA strain of TMEV virus (2 × 105 PFU) and the cells were
maintained in these conditions for 20 h. To identify the implication of
A2A receptors in the effects of CBD, the ZM241385 antagonist (0.1, 1
and 5 μM) was added 30 min before treatment. For ELISA assays of
the sVCAM-1 adhesion molecule the supernatants of the cell cultures
were collected.
Adhesion experiments
Brain endothelial cells were plated as described above at a density
of 105 cells/ml and they were then infected with the DA strain of
TMEV virus (2 × 105 PFU) for 4 h. Next, 2 × 105 leukocytes from the
lymphatic nodes of experimental animals (vehicle or CBD-treated
sham and TMEV animals, 8 days p.i.) were homogenized in cold phos-
phate buffer saline (PBS) with the plunger of a syringe, they were
then ﬁltered through a 70 μmcell strainer to obtain a single cell suspen-
sion, centrifuged for 5 min at 1200 rpm and resuspended in RPMI
supplemented with 10 mM HEPES (pH 7.4), 2 mM glutamine, 10%
FBS and β-mercaptoethanol (50 μM). The leukocytes were then stained
with calcein acetoxymethyl ester (AM, 5 μM) and allowed to adhere to
the endothelial monolayer for 20 h. Non-bound leukocytes were re-
moved, and adhered leukocytes were counted in 5 ﬂuorescence and
phase contrast microphotographs/ﬁeld using MetaMorph software, as
described previously (Mestre et al., 2011).
Astrocyte cell culture and stimulation with IL-1β and TNFα
Rat astrocyte cultures were prepared from postnatal Wistar pups
(0–2 days after birth) as described previously (Mecha et al., 2011).
After isolation, astrocytes were grown in poly-D-lysine-coated 12-well
sterile plates at a density of 5 × 105 cells/ml medium using DMEM
supplemented with 10% horse serum (HS), 2 mM glutamine, 100 U/ml
penicillin and 100 mg/ml streptomycin. The medium was switched
24 h later to DMEM alone for 1 h, and the cells were then incubated
for 6 h with IL-1β + TNFα (10 ng/ml each) and with CBD (1 or 5 μM,
Tocris, Bristol, UK) or the vehicle alone (70% ethanol). The CCL-2 chemo-
kine was assayed in the supernatants of the cell cultures by ELISA.
ELISA analysis
The CCL2 content in astrocyte cultures and the VCAM-1 content in en-
dothelial cultures were measured by solid phase sandwich ELISA, using
monoclonal antibodies speciﬁc for CCL2 and the soluble fraction of
VCAM-1, respectively. The CCL2 and sVCAM-1 contents in the supernatants
were quantiﬁed according to the manufacturer's instructions using
rat-speciﬁc CCL2 (Biosource International, CA, USA) and mouse-speciﬁc
sVCAM-1 ELISA kits (R&D Systems, MN, USA). The sensitivity of the assays
was 4.7 pg/ml for CCL2 and 30 pg/ml for sVCAM-1.
Reverse transcription (RT) and real-time polymerase chain reaction
(PCR)
Total RNA was extracted from nervous tissue (prefrontal cortex and
spinal cords) or from cell cultures using RNeasy mini columns (Qiagen,
UK). Genomic DNA contamination was avoided by DNase I degradation
(Qiagen, UK) and theRNA yieldwas determined using aNanodrop spec-
trophotometer (Nanodrop Technologies). Total RNA (1 μg in 20 μL) was
reverse transcribed into cDNA using poly-dT primers and the Promega
reverse transcription kit (Promega, Spain). Primers were (Applied
Biosystems, UK) TNFα: sense (GACTCCCCCCTCCGTCTAAG) and antisense(CGCAGTAAAGCCCACGTTGT); Il-1β: sense (TGGTGTGTGACGTTCCCATT)
and antisense (TCCATTGAGGTGGAGAGCTTTC); CCL2: sense (AGCAGG
TGTCCCAAAGAAGCTGTA) and antisense (AAAGGTGCTGAAGACCTTA
GGGCA); CCL5: sense (TCGTGCCCACGTCAAGGAGTATTT) and antisense
(TCTTCTCTGGGTTGGCACACACTT); CCR2: sense (GGCCACCACACCGTAT
GACT) and antisense (ACATGTTGCCCACAAACCAAAG); and 18S: sense
(ATGCTCTTAGCTGAGTGTCCCG) and antisense (ATTCCTAGCTGCGGTAT
CCAGG). SYBR® PCRwas performed using 1 μL of cDNA (corresponding
to 50 ng RNA input) in a Universal TaqMan Mastermix with 100 nM
primers and 50 nM probe. Cycling conditions were as follows: 50 °C
for 2 min; 95 °C for 10 min; and 40 ampliﬁcation cycles of 95 °C for
15 s and 60 °C for 1 min. Samples were assayed using the Applied
Biosystems PRISM 7500 sequence detection system, assaying each sam-
ple in triplicate and running a 6-point standard curve in parallel. To en-
sure the absence of contaminationwith genomic DNA, a control sample
using RNA as the template was run for each set of extractions. Relative
quantiﬁcation was obtained by calculating the ratio between the values
obtained for each gene of interest and those of the 18S house-keeping
gene. The results are expressed as a percentage with respect to the
sham animals for each time point.
Data analysis
All the data are expressed as the mean ± SEM. One-way ANOVA
followed by the Bonferroni post-hoc test or Kruskal–Wallis ANOVA
followed byMann–Whitney U testwas used to determine the statistical
signiﬁcance in all cases. The level of signiﬁcance was set at p ≤ 0.05.
Results
CBD decreases VCAM-1 and chemokine expression in vivo and in vitro
VCAM-1 is a member of the immunoglobulin supergene family
that is mainly expressed by endothelial cells and that binds selectively
to VLA-4 expressed by monocytes and lymphocytes (Engelhardt, 2008).
A rapid increase in VCAM-1 expression was detected in the brains of
TMEV-infected animals but not in sham animals (Fig. 1A), consistent
with previous ﬁndings (Brosnan et al., 1995; Mestre et al., 2009). How-
ever, when mice were administered CBD for 7 consecutive days imme-
diately after infection VCAM-1 expression remained at control levels in
the brain, as revealed by immunohistochemistry (Fig. 1A). Indeed,
ELISA analysis of sVCAM-1 in endothelial cells revealed that CBD
completely blocked TMEV-induced release of this adhesion molecule
(Fig. 1B; p ≤ 0.001). This block in VCAM-1 expression was conﬁrmed
when in vitro cell adhesion was assessed. Accordingly, lymphocytes
from TMEV-infected animals (8 days p.i.) exhibited increased adher-
ence to a monolayer of endothelial cells previously infected with
TMEV (p ≤ 0.001), while those extracted from TMEV-infected mice
treated with CBD did not adhere to endothelial stimulated cells to the
same extent (p ≤ 0.001).
The upregulation of the chemokines CCL2 and CCL5 in the spinal
cord of TMEV-IDD mice has been associated with the development
of the clinical disease (Hoffman et al., 1999). Thus, we investigated
whether TMEV induces the expression of these molecules in the pre-
frontal cortex of infected mice. In the acute phase of infection with
TMEV, we observed strong increases in the expression of CCL2, CCL5
and the CCR2 receptor mRNA (Fig. 2A). CBD treatment signiﬁcantly
reduced the expression of the CCL2 and CCL5 transcripts (p ≤ 0.05),
and it appeared to produce a slight but not signiﬁcant decrease in
CCR2 expression (p value = 0.460). The effect of CBD on chemokine
induction was also analyzed using in vitro approaches (Fig. 2B). CBD
treatment (1 and 5 μM) had no effect on basal CCL2 release in astro-
cyte cultures, while stimulation of these cells with IL-1β + TNFα
resulted in the release of CCL2 into the culture medium (as measured
by ELISA). Interestingly, at both doses CBD signiﬁcantly decreased
CCL2 release, with the greatest effect observed at 5 μM (p ≤ 0.001).
Fig. 1. CBD inhibits VCAM-1 production in response to TMEV infection and reduces leukocyte adhesion to endothelial cells. (A) Immediately after viral infection, sham and
TMEV-infected mice were treated for 7 consecutive days with CBD (5 mg/kg) or the corresponding vehicle alone (n = 6 per group). Representative microphotographs of coronal
brain sections (30 μm) immunostained for VCAM-1 showing positive staining in the blood vessels of TMEV-infected mice treated with the vehicle alone. Scale bar = 100 μm.
(B) ELISA determination of sVCAM-1 levels in supernatants of endothelial cell cultures 20 h after treatment. TMEV-infected cells were pretreated for 1 h with CBD (1 μM). The re-
sults represent the mean ± SEM from 3 independent experiments performed in triplicate: ***p ≤ 0.001 vs. control; ###p ≤ 0.001 vs. TMEV-infected cells; Kruskal–Wallis ANOVA
followed by Mann–Whitney U-test. (C) Brain endothelial cell monolayers were stimulated with TMEV virus for 6 h, and treated with vehicle or CBD (1 μM), and leukocytes from
sham and TMEV-infected mice were stained with AM-calcein (5 μM), and then added to the endothelial culture for 20 h. Graph represents leukocyte adherence to the endothelial
monolayer with respect to the control group (n = 6): *p ≤ 0.05, ***p ≤ 0.001 vs. control; ### p ≤ 0.001 vs. leukocytes from TMEV-Veh animals; Kruskal–Wallis ANOVA followed
by Mann–Whitney U-test.
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and it exerts anti-inﬂammatory effects in vivo
We investigated whether the regulatory effect of CBD on VCAM-1
and chemokine expression also altered neuroinﬂammation in TMEV-
infected mice 8 days p.i. As revealed by H&E staining (Fig. 3A), intrace-
rebral infection with TMEV promoted a strong inﬁltration of immune
cells into the brain parenchyma at different sites, including the cerebral
cortex and striatum. Moreover, CBD treatment decreased the inﬁltrate
score (Fig. 3B) to that of sham infected animals, an effect that was
particularly prominently close to the blood vessels where perivascular
cufﬁng was observed in TMEV-infected animals. By contrast, no inﬁl-
trates were detected in mice administered CBD. In line with these ﬁnd-
ings, CBD treatment signiﬁcantly reduced microglial activation in the
cerebral cortex (p ≤ 0.01), as revealed by Iba-1 staining (Figs. 4A, C).
The microglia in TMEV-infected mice displayed the typical activated,
ameboid morphology, whereas those isolated from CBD-treated mice
exhibited a ramiﬁed morphology similar to that of the sham infected
animals. Indeed, the immunosuppressive effect of CBD was accompa-
nied by a decrease in IL-1β expression (Fig. 4B; p ≤ 0.05), suggesting
that the mode of action of CBD involves the restriction of immune cell
transmigration to the CNS, as well as neuroinﬂammatory processes
that occur after TMEV infection.
Long term immunomodulatory effects of CBD in the TMEV model
As CBD appears to be beneﬁcial when administered in the induction
phase of the TMEV-IDD model, we investigated whether the immuno-
regulatory actions of CBD have long term effects on the onset ofsymptoms, and on the spinal cord inﬂammation that occurs in the
chronic phase of the disease. Mice were treated for 10 days with CBD
immediately after infection with TMEV and on day 80, motor function
was evaluated and histological and PCR analyses were performed. CBD
treatment in the acute phase of the disease impaired disease progres-
sion in the chronic phase of TMEV-IDD, restoring both horizontal and
vertical motor activities to that of the sham infected mice (Figs. 5A, B;
p ≤ 0.05). We next investigated whether CBD treatment also inﬂuenced
the neuroinﬂammation observed in the chronic phase of the disease, as
neurological dysfunction in the TMEV model has been traditionally as-
sociated with inﬂammation, demyelination and axonal loss in the
white matter of the spinal cord (Ure and Rodriguez, 2002). The effects
of CBD were accompanied by a reduction in microglial reactivity in
the spinal cord (Figs. 5C, D; p ≤ 0.001), and in the expression of the
proinﬂammatory cytokines TNFα and IL-1β (Figs. 6A, B; p ≤ 0.001),
consistent with the immunomodulatory effects of CBD observed in the
acute phase of TMEV infection.
Increased microglial reactivity is one of the events that occur at
the encephalic level in the TMEV-IDD model, and it is accompanied
by neurodegeneration and demyelination (Mecha et al., 2012b).
CBD administration in the initial phase of TMEV infection signiﬁcantly
attenuated this process in the cerebral cortex during the chronic
phase (Figs. 6C, D; p ≤ 0.05).
Involvement of adenosine A2A receptors in the effects of CBD in vivo and
in vitro
Among themany pharmacological effects of CBD, some of its immu-
nosuppressive actions may be independent of cannabinoid receptor
Fig. 3. CBD decreases leukocyte inﬁltration in the brains of TMEV-infected animals. Coronal brain sections (30 μm thick) were obtained at day 8 p.i. and stained with hematoxylin–eosin.
(A) TMEV infection induced increases in leukocyte inﬁltration to several areas of the brain, particularly around blood vessels. Scale bar = 200 μm. (B) This effect was attenuated by CBD
treatment (5 mg/kg), as indicated by the inﬁltrate score in the cerebral cortex, striatum and blood vessels.
Fig. 2. CBD treatment decreases chemokine induction. (A) RT-PCR revealed that CBD treatment (5 mg/kg) decreased CCL2, CCL5 and CCR2 mRNA induction in the prefrontal cortex
of TMEV-infected animals. The mRNA expression of each gene (n = 6 per group) was normalized to that of the 18S gene and the data represent the mean ± SEM: ***p ≤ 0.001 vs.
sham; #p ≤ 0.05 vs. TMEV-Veh animals; Kruskal–Wallis ANOVA followed by Mann–Whitney U-test. (B) CCL2 levels were measured by ELISA in supernatants of cell astrocyte
cultures 6 h after treatment, where IL-1β + TNFα-stimulated cells were pretreated for 1 h with CBD (1 or 5 μM). The results represent the means ± SEM from 3 independent
experiments performed in triplicate: ***p ≤ 0.001 vs. control; ##p ≤ 0.01, ###p ≤ 0.001 vs. stimulated astrocytes; Kruskal–Wallis ANOVA followed by Mann–Whitney U-test.
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Fig. 5. CBD treatment for 7 days p.i. amelioratesmotor deﬁcits and decreasesmicroglial reactivity in the chronic phase of TMEV infection. Sham and TMEV-infectedmicewere treated for
10 consecutive days with CBD (5 mg/kg) or the vehicle alone (n = 6 per group) immediately after viral infection, and they were analyzed on day 80 post-infection. Motor function was
evaluated bymeasuring horizontal (A) and vertical (B) activities in the activity cage test, revealing a signiﬁcant attenuation of motor deﬁcits in the TMEV-IDDmodel following CBD treat-
ment. Activity parameterswere recorded for 10 min, and the results represent themean ± SEMof 6mice per group: *p ≤ 0.05, ***p ≤ 0.001 vs. sham; #p ≤ 0.05 vs. TMEV-Veh animals;
one-way ANOVA followed by Tukey's test. (C) CBD treatment decreasedmicroglial reactivity in the spinal cord of TMEV-infected animals whenmeasured in the chronic phase of the dis-
ease. Quantiﬁcation of the percentage area occupied by microglia in per spinal cord ﬁeld, expressed as the mean ± SEM: ***p ≤ 0.001 vs. sham; ###p ≤ 0.001 vs. TMEV-Veh animals;
one-way ANOVA followed by Tukey's test. (D) Representative microphotographs of spinal cord sections from the aforementioned mice, cut at the cervical level and immunostained for
microglia (Iba1). Scale bar = 100 μm.
Fig. 4. CBD treatment attenuates themicroglial response to TMEV infection. Coronal brain sections (30 μm thick) were obtained at day 8 p.i. and stained for Iba1. (A) Quantiﬁcation of the per-
centage area occupied bymicroglia in the cerebral cortex perﬁeld (n = 6 animals per group): ***p ≤ 0.001 vs. sham; ##p ≤ 0.01 vs. TMEV-Veh animals: one-wayANOVA followed by Tukey's
test. (B) CBD treatment decreased IL-1βmRNA induction as determined by RT-PCR, in the prefrontal cortex of TMEV-infected animals, normalizingmRNA expression (n = 6 per group) to that
of the 18S gene. Data represent the mean ± SEM: ***p ≤ 0.001 vs. sham; #p ≤ 0.05 vs. TMEV-Veh animals; Kruskal–Wallis ANOVA followed by Mann–Whitney U-test. (C) Representative
microphotographs of Iba1 immunostaining in the above animals, showing morphological changes in the microglial cells of infected animals. Typical activated Iba1+ cells are evident in the
cerebral cortex of TMEV-infected mice, while in sham and TMEV-infected mice treated with CBD (5 mg/kg), ramiﬁed, non-activated microglial cells are prominent. Scale bar = 100 μm.
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ceptor, they may involve enhanced adenosine signaling (Malfait et al.,
2000; Ribeiro et al., 2012). To explore this hypothesis, mice were ad-
ministered with the selective A2A antagonist ZM241385 at the time of
TMEV infection and 30 min later, they were treated with CBD. In the
brains of infected mice ZM241385 treatment attenuated some of the
effects of CBD, including its inhibition of VCAM-1 expression (Fig. 7A)
and of immune cell inﬁltration (Fig. 7B) and the reduction of Iba-1
immunoreactivity (Fig. 7C and Table 1). The administration of the an-
tagonist did not have any effect in TMEV animals by itself. These obser-
vations suggest that the A2A receptor is at least partially involved in the
effects of CBD, as further supported by the dose–response effects of this
A2A antagonist on brain endothelial cell cultures in vitro. A2A receptor
antagonism with ZM241385 had a dose–effect blockade action, as at
the dose of 5 μM (Table 2) completely blocked the inhibitory effects of
CBD on sVCAM-1 release, determined by ELISA (p ≤ 0.001), whereas
the antagonism alone did not exert any effect in TMEV induced libera-
tion of VCAM-1 (data not shown).
Discussion
In the present work we demonstrate that CBD counteracts some of
the deleterious inﬂammatory responses to TMEV infection in the
mouse brain. Sub-chronic treatment with CBD after TMEV inoculation
of susceptible mice decreased the levels of several CNS mediators in-
duced by viral infection, including VCAM-1, the chemokines CCL2 and
CCL5, and the pro-inﬂammatory cytokine IL-1β. Similarly, this treat-
ment decreased leukocyte inﬁltration and microglial activation, alter-
ing motor symptomatology and the neuroinﬂammation in the chronic
phase of infection. These effects were also observed in cultured cellsFig. 6. CBD treatment exerts long-term effects that are evident in the chronic phase of TMEV
reduced microglial reactivity in the cerebral cortex. CBD treatment (5 mg/kg) decreased TN
determined by RT-PCR normalizing mRNA expression (n = 6 per group) to that of the 18S gen
animals; Kruskal–Wallis ANOVA followed byMann–Whitney U-test. Early CBD treatment also d
sured in the chronic phase of the disease. (C) Quantiﬁcation of the percentage area occupied by
#p ≤ 0.05 vs. TMEV-Veh animals; one-wayANOVA followedby Tukey's test. (D) Representative
(Iba1). Scale bar = 100 μm.in vitro, and they appear to be mediated at least in part by the A2A
adenosine receptor.
The recruitment of activated immune cells through the endothelial
cells of the BBB appears to be an essential step in the initiation of CNS
inﬂammation in MS. In the brain and in endothelial cell cultures, CBD
limited leukocyte migration to the nervous parenchyma in the acute
phase of TMEV-IDD, probably by decreasing VCAM-1 expression,
which reduced the adhesion of lymphocytes to endothelial cells and re-
duced inﬁltration in response to viral infection. These results are sup-
ported by our previous demonstration that impairing the upregulation
of VCAM-1 following TMEV-IDD in vitro and in vivo attenuates the in-
ﬂammatory responses and ameliorates the deﬁcits produced (Mestre
et al., 2009, 2011). CBD pretreatment also attenuates the high-glucose
endothelial cell inﬂammatory response by decreasing VCAM-1 ex-
pression (Rajesh et al., 2007). It should be noted that the soluble
fractions of VCAM-1 (sVCAM-1) increase in the cerebrospinal
ﬂuid and serum of MS patients in parallel with the progression of clini-
cal disease (Correale and Bassani Molinas, 2003; Giovannoni et al.,
1997; Hartung et al., 1995; Rieckmann et al., 1997). Accordingly,
blocking the induction of this adhesionmolecule appears to be essential
to regulate the transmigration of activated cells from peripheral lym-
phoid tissues.
Chemokine release is another crucial step in the recruitment of
inﬂammatory cells to the CNS. Chemokines are a family of lowmolecular
weight, inducible, secreted, pro-inﬂammatory cytokines, which serve as
potent chemoattractants for immune cells, thereby regulating their re-
cruitment, trafﬁcking and activation (Glass et al., 2003; Oppenheim
et al., 1991). Pioneering studies in the TMEV-IDD model demonstrated
that the increase in chemokine levels in the spinal cord is associated
with the development of clinical symptoms (Hoffman et al., 1999) and-IDD, including decreased pro-inﬂammatory cytokine production in the spinal cord and
Fα (A) and IL-1β (B) mRNA induction in the spinal cord of TMEV-infected animals, as
e. Data represent the mean ± SEM: ***p ≤ 0.001 vs. sham; ###p ≤ 0.001 vs. TMEV-Veh
ecreasedmicroglial reactivity in the cerebral cortex of TMEV-infected animals whenmea-
microglia per cerebral cortex ﬁeld, expressed as themean ± SEM: ***p ≤ 0.001 vs. sham;
microphotographs of cerebral sections from the abovemice, immunostained formicroglia
Table 2
Fig. 7. A role for A2A receptors in the mechanism of action of CBD in vivo. Immediately after viral infection, sham and TMEV-infected mice were treated for 7 consecutive days with
the A2A antagonist ZM241385 (5 mg/kg) 30 min before treatment with CBD (5 mg/kg) or the corresponding vehicle alone (n = 6 per group). Representative microphotographs of
coronal brain sections (30 μm) showing VCAM-1 immunostaining (A), leukocyte inﬁltration (hematoxylin–eosin staining; B) and microglial activation (Iba1 immunostaining; C), show
that A2A antagonism did not exert any effect in TMEV infected mice, whereas it partially blocked the effects of CBD in the acute phase of TMEV infection. Scale bar = 100 μm.
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cytes in the foci of active inﬂammation (Deshmane et al., 2009). Our re-
sults indicate that CBD limits chemokine production, as CCL2 and CCL5
expression decreased signiﬁcantly in TMEV-infected mice treated with
CBD. Moreover, our ﬁndings suggest an important immunoregulatory
effect of CBD, which may limit the recruitment of lymphocytes to lesion
sites by acting at both microglia and astrocytes. Indeed, anti-CCL2 treat-
ment inhibits TMEV-IDD by decreasingmononuclear cell inﬁltration and
CNS inﬂammation (Karpus et al., 2006). InMSpatients, CCL2 is present in
astrocytes and macrophages of active lesions, while CCL5 is present in
lesions associated with the recruitment of T lymphocytes (Szczucinski
and Losy, 2007). Here, the ability of CBD to inhibit VCAM-1 upregulation,
together with its attenuation of the chemokine response, may explain
the reduced immune cell inﬁltration seen in the brains of infected ani-
mals. In support of this view, it was previously demonstrated that CBD
decreases leukocytemigration to the lungs in amodel of acute inﬂamma-
tory injury (Ribeiro et al., 2012), and CBD exerts anti-inﬂammatory
effects at the vascular level following endotoxic shock induced by LPS
(Ruiz-Valdepenas et al., 2011).
In addition to the effects of CBD at the level of the BBB, we found
that this phytocannabinoid also interferes with the development ofTable 1
A role for A2A receptors in the mode of action of CBD in microglial cells in vivo. Quan-
tiﬁcation of the percentage area occupied by microglia in the cerebral cortex per ﬁeld,
using ZM241385 (5 mg/kg) 30 min before CBD treatment. The results represent the
means ± SEM (n = 6 animals per group): ***p ≤ 0.001 vs. TMEV + Veh animals;
###p ≤ 0.001 vs. TMEV + CBD; Kruskal–Wallis ANOVA followed by Mann–Whitney
U-test.
Mean SEM
TMEV + Veh 900.84 50.67
TMEV + ZM 918.00 ns 44.56
TMEV + CBD 102.33*** 4.99
TMEV + CBD + ZM 191.45### 16.31a deleterious inﬂammatory response in the brain of TMEV-infected
animals in early disease stages. CBD treatment decreased microglial
activation (as evident by immunohistochemistry) and the production
of the pro-inﬂammatory cytokine IL-1β, mainly produced by macro-
phages/microglia. In TMEV-IDD, glial cells produce cytotoxic inﬂam-
matory mediators that contribute to the myelin loss and axonal
damage characteristic of this model (Pope et al., 1996). Cannabinoids
suppress the production of pro-inﬂammatory cytokines, including
TNFα, IL-1β, IL-2, IL-6, IL-12 and IFN-γ, as well as mitogen-induced
cell proliferation, migration, antigen presentation and trafﬁcking to
inﬂamed tissues (Croxford et al., 2005; Kozela et al., 2010; Rieder
et al., 2012; Tanasescu and Constantinescu, 2010). Moreover, in a pro-
gressive EAE model, administration of CBD (5 mg/kg) during disease
onset ameliorates disease severity by diminishing microglial cell acti-
vation and pathogenic T cell and immune cell inﬁltration in the spinal
cord of immunized animals (Kozela et al., 2011). However, in a re-
lapsing–remitting EAE model by inoculation of murine spinal cord
homogenate, CBD at a dose range of 0.5 to 25 mg/kg for days 10 to
22 post-immunization did not alter clinical score while THC wasA role for A2A receptors in the mode of action of CBD in endothelial cells in vitro.
sVCAM-1 levels in the supernatant of endothelial cell cultures were measured by
ELISA 20 h after treatment. Endothelial cells were pretreated for 30 min with distinct
concentrations of the antagonist ZM241385 (0.1, 1 and 5 μM), followed by CBD
(1 μM) for 1 h before infection with TMEV. The results represent the means ± SEM
from 3 independent experiments performed in triplicate: ***p ≤ 0.001 vs. TMEV-Veh;
#p ≤ 0.05 vs. TMEV + CBD; ##p ≤ 0.01 vs. TMEV + CBD; Kruskal–Wallis ANOVA
followed by Mann–Whitney U-test.
Mean SEM
TMEV + Veh 3.300 0.077
TMEV + CBD 0.133*** 0.019
TMEV + CBD + ZM 0.1 μM 0.300 ns 0.022
TMEV + CBD + ZM 1 μM 1431# 0.037
TMEV + CBD + ZM 5 μM 3304## 0.172
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sive MS vs. RRMS or administration schedules may account for the
discrepant results among the labs. The data in the MS progressive
models are consistent with the long-term anti-inﬂammatory effects
of CBD treatment in the early stages of TMEV-IDD, which impaired
early symptomatology in infected animals and decreased microglial
activation and pro-inﬂammatory cytokine production in the chronic
phase of the disease. It appears that attenuation of the early deleterious
response of the peripheral and resident immune system has positive
effects in the chronic phase of viral infection, resulting in less severe
neurological deﬁcits.
Although CBD exerts its effects through a variety of signaling path-
ways (reviewed in Izzo et al., 2009; Zuardi, 2008), adenosine A2A recep-
tors appear to be involved in some of its anti-inﬂammatory effects
(Carrier et al., 2006). Treatment with ZM241385, a highly selective A2A
antagonist, attenuated many of the anti-inﬂammatory effects of CBD,
including its effects on VCAM-1 expression (in vivo and in vitro), leuko-
cyte inﬁltration and microglial activation in early disease stages. It was
previous demonstrated that A2A receptor activation attenuates inﬂam-
matory responses in a model of acute lung injury (Impellizzeri et al.,
2011; Reutershan et al., 2007), while the inactivation of this receptor
exacerbates EAE pathology (Yao et al., 2012) and blockade abrogates
the anti-inﬂammatory effects of CBD (Ribeiro et al., 2012), consistent
with our ﬁndings. Moreover, treatment with a speciﬁc A2A receptor
agonist decreases neutrophil and macrophage recruitment while re-
ducing VCAM-1 immunoreactivity in amurine carotid ligationmodel
(McPherson et al., 2001). In our experimental conditions, A2A recep-
tor blockade completely reversed the effects of CBD in endothelial
cells, whichmay explain the observed attenuation of immune cell inﬁltra-
tion and microglia activation in the brain. While we cannot rule out the
participation of other receptors in the mechanism of action of CBD, an-
tagonists of CB1, CB2, PPARγ and TRPV1 failed to alter its effects in vitro
(data not shown). Thus, it appears that inhibition of adenosine uptake
and signaling via the adenosine A2A receptor is one of the main mecha-
nisms by which CBD exerts its anti-inﬂammatory effects in TMEV-IDD
by modulating the VCAM-1 expression, although other actions of CBD
such as inhibition of anandamide reuptake (Bisogno et al., 2001), CB2
inverse agonism (Thomas et al., 2007) or the inhibition of fatty acid
amide hydrolase (FAAH), may also contribute to its anti-inﬂammatory
effects.
There is a need for novel therapeutic strategies for MS and despite
emerging evidence demonstrating the putative therapeutic effects of
cannabinoids, their effective introduction into clinical use is strongly
limited by unwanted psychotropic effects (Iuvone et al., 2009). However,
in 2005 a mixture of THC and CBD administered as an oromucosal spray
(Sativex®) was approved for the treatment of MS symptoms (Perras,
2005). CBD iswell tolerated in humans, it has low toxicity and no psycho-
active activity, and it exerts interesting immunomodulatory, antioxidant,
neuroprotective (El-Remessy et al., 2008; Hampson et al., 1998; Iuvone
et al., 2009) and oligoprotective effects (Mecha et al., 2012a), which
may underlie its possible pleiotropic effects in neuroinﬂammatory
pathologies. The present ﬁndings reveal an attractive therapeutic
proﬁle of CBD and suggest that CBD will have efﬁcacy in controlling
neuroinﬂammatory diseases such as MS. This compound can limit
the harmful effects of an exacerbated inﬂammatory response, likely by
increasing adenosine signaling, and prevent the development of sec-
ondary and irreversible damage.
Conclusions
In this study we present evidence that the non-psychotropic canna-
binoid CBD has beneﬁcial immunoregulatory actions in the TMEV-IDD
model. CBD decreases the transmigration of blood leukocytes to the ner-
vous parenchyma by downregulating the expression of VCAM-1 and the
chemokines CCL2 and CCL5 and diminishes the activation of microglial
cells in the early stages of the disease. Moreover, the treatment withCBD has long-term positive effects in TMEV-IDD and improves motor
deﬁcits associated with the disease. Finally, adenosine A2A receptors
are involved in the CBD-induced reduction of VCAM-1 by endothelial
cells, deﬁning a novel mode of action of CBD in neuroinﬂammatory
processes.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.nbd.2013.06.016.Acknowledgments
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